Q-omics provides the consensus-scored CXorf66 profile across patient tissues and cancer cell-line models. CXorf66 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CXorf66 is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, CXorf66 RNA expression shows 6,408 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LIHC, and STAD as cancer lineages where CXorf66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXorf66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXorf66 survival associations across molecular data types. CXorf66 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXorf66 RNA expression–survival associations across cancer types. High CXorf66 expression shows unfavorable associations in UCEC, LUAD, READ, MESO, THCA and CHOL. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CXorf66 RNA expression.
This table summarizes CXorf66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CXorf66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXorf66 shows lower tumor expression in LIHC, CHOL and KIRC. The LIHC box plot shows higher CXorf66 RNA expression in normal versus tumor tissue (log2 FC = −0.289, t-test p < 0.001).
This table shows molecular features associated with CXorf66 in patient tissues and cancer cell lines. In patient samples, CXorf66 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CXorf66 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
